Drug Therapy

Adult cancer drug offers hope against aggressive pediatric brain tumor

By

The quest to improve survival of children with a high-risk brain tumor has led investigators to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers.

New drug successful against crizotinib-resistant, ALK-positive lung cancer

By

A new drug, ceritinib, appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.

Exceptional response to everolimus is reported in patient with bladder cancer patient

By

A patient with advanced bladder cancer experienced a complete response to the drug combination everolimus and pazopanib in a phase 1 clinical trial. Genomic profiling revealed information that could help identify other patients who may respond to everolimus and pazopanib.

Experts praise drug trial for building a realistic study population

By

A German study of a new drug therapy for chronic lymphocytic leukemia (CLL) was lauded for including elderly persons who had other, coexisting health issues. An accompanying editorial noted that the study population more accurately represented patients with CLL.

Advocating for treatment of anticipatory reactions

Advocating for treatment of anticipatory reactions

By

What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?

Bone turnover markers predict prostate cancer outcomes

Bone turnover markers predict prostate cancer outcomes

By

Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).

Investigational drug may increase survival of advanced melanoma

By

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to an early-phase clinical trial.

Patient requests affect clinician prescribing behavior

Patient requests affect clinician prescribing behavior

Patients requesting specific medications are more likely to be prescribed those medications, according to research.

Antipsychotic medications offer hope against glioblastoma

By

Researchers have discovered that FDA-approved antipsychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.

Malaria drug may help overcome resistance to melanoma BRAF drugs

By

A never-before-seen autophagy mechanism induced by the BRAF inhibitors vemurafenib and dabrafenib explains the resistance that melanoma develops to these BRAF inhibitors, according to new research.

Advanced approach invented to ID drug candidates from genome sequence

By

In research that could ultimately lead to many new medicines, scientists have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.

Potential therapy for rare, drug-resistant GISTs

By

By screening a library of US FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, scientists were surprised to find several potential possibilities.

Out-of-pocket costs influence adherence to treatment

Out-of-pocket costs influence adherence to treatment

Many patients skip doses or stop taking medication entirely when their share of the costs becomes too high.

TCGA study of bladder cancer reveals potential drug targets

TCGA study of bladder cancer reveals potential drug targets

By

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer.

Blueprint for action issued to combat oncology drug shortages

By

A group of prominent health care experts including bioethicists, pharmacists, policymakers, and cancer specialists have proposed concrete steps for preventing shortages of life-saving drugs.

Out-of-pocket costs determine treatment adherence for cancer patients

Out-of-pocket costs determine treatment adherence for cancer patients

By

When a patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to new research.

Coordinated approach is needed for castrate-resistant prostate cancer

By

With a deluge of promising new treatments for advanced prostate cancer, a new model of care is needed that emphasizes collaboration between urology and medical oncology clinicians.

Pediatric Cancer Genome Project finds promising family of drugs for rhabdomyosarcoma

By

Drugs that enhance oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor. These are the latest findings from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project

Ramucirumab prolongs survival in advanced gastric cancer

By

An investigational drug improved median survival while reducing risk of disease progression or death in persons with metastatic gastric cancer participating in the phase III REGARD trial.

A roundup of FDA oncology news from September 2013

By

The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.

Turmeric spice may have role in multiple myeloma therapy

Turmeric spice may have role in multiple myeloma therapy

By

Hybrid compounds formed from structural features of the antinausea agent thalidomide and curcumin destroyed multiple myeloma cells in recent lab experiments.

A single protein affects susceptibility of cancer cells to chemotherapy

By

A newly discovered weakness in cancer cells may make them more susceptible to chemotherapy and other treatments.

Pre-chemotherapy treatment delays return of aggressive lymphoma

By

In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.

New magnetic resonance analysis reveals brain tumor response to anti-angiogenesis therapy

By

A new way of analyzing data acquired in magnetic resonance imaging appears to identify whether or not tumors are responding to anti-angiogenesis therapy.

Drug reduces prostate cancer risk but has no impact on survival

By

After 18 years of follow-up, the drug finasteride was shown to reduce the risk for prostate cancer by approximately one third, but did not significantly affect overall survival in men or survival after prostate cancer diagnosis.

A roundup of FDA oncology news from August 2013

By

The FDA granted marketing approval to an orphan drug for the topical treatment of stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma (CTCL).

Aggressive breast cancer may be sensitive to drugs attacking their waste disposal

Aggressive breast cancer may be sensitive to drugs attacking their waste disposal

By

Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome. The proteasome is the cellular structure that disposes the waste of the cell by breaking down damaged or unneeded proteins

Myeloma drug fights CNS lymphoma

By

The drug pomalidomide, already approved for use in persons with multiple myeloma, is a promising therapeutic agent for central nervous system (CNS) lymphoma, say investigators.

Interleukin-2 extends life in melanoma brain metastases

By

Researchers are suggesting that high-dose interleukin-2 (HD IL-2) therapy should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy, based on the encouraging results of a small retrospective review.

Radium-223 prolongs life in advanced prostate cancer

By

Radium-223 dichloride (Xofigo) significantly improved overall survival and caused few adverse events in men with castration-resistant prostate cancer (CRPC) that had metastasized to bone, researchers reported.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs